How big is Dynavax Technologies Corp.?

As of Jun 18, Dynavax Technologies Corp. has a market capitalization of 1,199.61 million and reported net sales of 294.62 million with a net profit of -60.07 million over the latest four quarters. Shareholder's funds are 596.80 million, and total assets amount to 986.26 million.

As of Jun 18, Dynavax Technologies Corp. has a market capitalization of 1,199.61 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 294.62 million, while the sum of net profit for the same period is -60.07 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 596.80 million, and the total assets amount to 986.26 million.

What does Dynavax Technologies Corp. do?

Dynavax Technologies Corp. is a clinical-stage immunotherapy company that focuses on stimulating immune responses through toll-like receptor activation. As of March 2025, it reported net sales of $68 million and a net loss of $96 million, with a market cap of approximately $1.2 billion.

Overview: <BR>Dynavax Technologies Corporation is a clinical-stage immunotherapy company focused on leveraging the body's immune responses through toll-like receptor stimulation, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market classification.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 68 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -96 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,199.61 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 54.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.75 <BR>Return on Equity: 4.27% <BR>Price to Book: 2.26<BR><BR>Contact Details: <BR>Address: 2100 POWELL STREET, SUITE 900, EMERYVILLE CA: 94608 <BR>Tel: 1 510 8485100 <BR>Fax: 1 510 8481327 <BR>Website: http://www.dynavax.com/

Should I buy, sell or hold Dynavax Technologies Corp.?

Who are in the management team of Dynavax Technologies Corp.?

As of March 2022, the management team of Dynavax Technologies Corp. includes Dr. Andrew Hack (Interim Independent Chairman), Ryan Spencer (CEO), and directors Julie Eastland, Brent MacGregor, Peter Paradiso, Francis Cano, and Daniel Kisner. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Dynavax Technologies Corp. includes the following individuals:<BR><BR>- Dr. Andrew Hack, Interim Independent Chairman of the Board<BR>- Mr. Ryan Spencer, Chief Executive Officer and Director<BR>- Ms. Julie Eastland, Director<BR>- Mr. Brent MacGregor, Director<BR>- Dr. Peter Paradiso, Director<BR>- Dr. Francis Cano, Independent Director<BR>- Dr. Daniel Kisner, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Dynavax Technologies Corp. overvalued or undervalued?

As of May 6, 2025, Dynavax Technologies Corp. is considered risky due to its high P/E ratio of 54, negative EV to EBITDA ratio of -832.88, and poor stock performance, indicating it may be overvalued compared to its peers and the broader market.

As of 6 May 2025, the valuation grade for Dynavax Technologies Corp. has moved from fair to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued, particularly given its high P/E ratio of 54, which significantly exceeds the industry average, and a PEG ratio of 0.58 that suggests potential growth is not adequately reflected in the current price. Additionally, the EV to EBITDA ratio is notably negative at -832.88, further highlighting valuation concerns.<BR><BR>In comparison to its peers, Dynavax's P/E ratio is higher than that of Blueprint Medicines Corp. at -53.75 and Axsome Therapeutics, Inc. at -29.91, both of which are also classified as risky. The company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -23.65% compared to the index's 12.22%, reinforcing the notion of overvaluation amidst a challenging market environment.

Is Dynavax Technologies Corp. technically bullish or bearish?

As of October 10, 2025, Dynavax Technologies Corp. is in a bearish trend, indicated by negative MACD readings and underperformance of 22% year-to-date compared to the S&P 500's 11.41% gain.

As of 10 October 2025, the technical trend for Dynavax Technologies Corp. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including bearish MACD readings on both weekly and monthly time frames, a bearish daily moving average, and bearish Bollinger Bands on the weekly chart. The KST shows a mildly bullish signal weekly, but this is overshadowed by the overall bearish trend. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 year-to-date, down 22.00% compared to the S&P's gain of 11.41%, and has also lagged over the past year with a return of -3.11% against the S&P's 13.36%.